TY - JOUR
T1 - Mechanisms of hyperoxia-induced reductions in retinal blood flow in newborn pig
AU - Zhu, Yun
AU - Park, T. S.
AU - Gidday, Jeffrey M.
N1 - Funding Information:
We thank Jennifer A. Meier, Ernesto Gonzales, Aarti R. Shah, and Raymond G. Maceren for their excellent technical assistance in this project and Carl Rovainen, Ph.D. for advice on angiogram image analysis procedures. We also thank Ron Tilton, Ph.D., from Texas Biotechnology Corporation, Houston, TX, for the generous supply of TBC 1241z, David S. Cohen, Ph.D. from CIBA-GEIGY Corporation, Summit, NJ, for supplying CGS 22652, and David R. Harder, Ph.D. for providing us DDMS. Supported by NIH grants EY 09678 and 02687.
PY - 1998/9
Y1 - 1998/9
N2 - Although reductions in retinal blood flow (RBF) in response to acute hyperoxia are well described, the mechanistic basis of this response has yet to be clarified. The present study was undertaken in order to determine the possible involvement of two arachidonic acid-derived vasoconstrictors, the cyclooxygenase metabolite thromboxane and the cytochrome P450 metabolite 20-HETE, as well as the involvement of the peptide endothelin and superoxide free radical. Fluorescein videoangiography was performed on the intact eyes of isoflurane-anesthetized newborn piglets. RBF responses to 20 min of hyperoxia were calculated from the angiograms off-line, using changes in mean arteriovenous transit times and arteriolar and venular diameters. The effect of hyperoxia (PaO2 = 351 ± 9 mmHg; n = 39) on RBF was examined in each animal under control conditions and again after intravitreal perivascular administration of drugs that block the synthesis or receptors of known vasoconstrictors. Estimated RBF decreased by a maximum of 42 ± 3% in the 7 animal groups in response to 20 min of hyperoxia. The magnitude and time course of the change in RBF resulting from two successive hyperoxic challenges did not differ, and were unaffected by intravitreal administration of vehicle. The response to hyperoxia was attenuated 46 ± 6 (n = 6; P = 0.001) after intravitreal CGS 22652 (2 nmol), a combined thromboxane synthesis inhibitor and receptor antagonist. DDMS (12.5 nmol), a competitive inhibitor of the P450 enzyme ω-hydroxylase that forms 20-HETE, blocked hyperoxic constriction by 23 ± 7% (n = 6; P=0.01). Intravitreal pretreatment with TBC 1241z (2 nmol), a receptor antagonist of the peptide endothelin, blocked the hyperoxic response by 26 ± 5% (n = 6; P= 0.01). A combination of CGS 22652 (2 nmol), DDMS (12.5 nmol), and TBC 1241z (2 nmol), blocked the hyperoxic flow response by 51 ± 3% (n = 5; P = 0.003). Administration of a combination of superoxide dismutase (10 U intravitreally, 10000 U kg-1 of the polyethylene glycol-conjugate intravenously) and catalase (10 U intravitreally, 10000 U kg-1 intravenously) was without effect on hyperoxia-induced reductions in RBF (n = 5). The present results indicate that the arachidonic acid metabolites thromboxane and 20-HETE, and the peptide endothelin, participate in mediating the acute reduction in RBF in response to hyperoxia.
AB - Although reductions in retinal blood flow (RBF) in response to acute hyperoxia are well described, the mechanistic basis of this response has yet to be clarified. The present study was undertaken in order to determine the possible involvement of two arachidonic acid-derived vasoconstrictors, the cyclooxygenase metabolite thromboxane and the cytochrome P450 metabolite 20-HETE, as well as the involvement of the peptide endothelin and superoxide free radical. Fluorescein videoangiography was performed on the intact eyes of isoflurane-anesthetized newborn piglets. RBF responses to 20 min of hyperoxia were calculated from the angiograms off-line, using changes in mean arteriovenous transit times and arteriolar and venular diameters. The effect of hyperoxia (PaO2 = 351 ± 9 mmHg; n = 39) on RBF was examined in each animal under control conditions and again after intravitreal perivascular administration of drugs that block the synthesis or receptors of known vasoconstrictors. Estimated RBF decreased by a maximum of 42 ± 3% in the 7 animal groups in response to 20 min of hyperoxia. The magnitude and time course of the change in RBF resulting from two successive hyperoxic challenges did not differ, and were unaffected by intravitreal administration of vehicle. The response to hyperoxia was attenuated 46 ± 6 (n = 6; P = 0.001) after intravitreal CGS 22652 (2 nmol), a combined thromboxane synthesis inhibitor and receptor antagonist. DDMS (12.5 nmol), a competitive inhibitor of the P450 enzyme ω-hydroxylase that forms 20-HETE, blocked hyperoxic constriction by 23 ± 7% (n = 6; P=0.01). Intravitreal pretreatment with TBC 1241z (2 nmol), a receptor antagonist of the peptide endothelin, blocked the hyperoxic response by 26 ± 5% (n = 6; P= 0.01). A combination of CGS 22652 (2 nmol), DDMS (12.5 nmol), and TBC 1241z (2 nmol), blocked the hyperoxic flow response by 51 ± 3% (n = 5; P = 0.003). Administration of a combination of superoxide dismutase (10 U intravitreally, 10000 U kg-1 of the polyethylene glycol-conjugate intravenously) and catalase (10 U intravitreally, 10000 U kg-1 intravenously) was without effect on hyperoxia-induced reductions in RBF (n = 5). The present results indicate that the arachidonic acid metabolites thromboxane and 20-HETE, and the peptide endothelin, participate in mediating the acute reduction in RBF in response to hyperoxia.
KW - Endothelin
KW - Fluorescein angiography
KW - Free radicals
KW - Hyperoxia
KW - Retinal blood flow
KW - Swine
KW - Thromboxane
UR - http://www.scopus.com/inward/record.url?scp=0032170702&partnerID=8YFLogxK
U2 - 10.1006/exer.1998.0535
DO - 10.1006/exer.1998.0535
M3 - Article
C2 - 9778417
AN - SCOPUS:0032170702
SN - 0014-4835
VL - 67
SP - 357
EP - 369
JO - Experimental eye research
JF - Experimental eye research
IS - 3
ER -